Content available at: https://www.ipinnovative.com/open-access-journals

Indian Journal of Clinical Anatomy and Physiology

Journal homepage: https://www.ijcap.org/

Review Article

Role of artificial intelligence in homeostatic disruption monitoring & Early disease detection

Khuspe Pankaj Ramdas[1], Swapnil Phade[1], Aboli Mundphane[1], Sitaram Kale[1]*, Dipali Mane[1], Abhijeet Survase[2]

[1]Dept. of Pharmacy, Shriram Shikshan Sanstha's College of Pharmacy, Paniv, Maharashtra, India
[2]Vidya-Niketan College of Pharmacy, Lakhewadi, Maharashtra, India

Abstract

Artificial Intelligence (AI) has emerged as a transformative tool in modern healthcare, giving new capabilities for real-time study and prediction of physiological trends. Homeostasis, the dynamic management of internal biological factors such as blood pressure, glucose concentration, core temperature, and pH, is crucial to preserving health. Disruption in homeostatic homeostasis often serves as an early sign of pathological diseases. Conventional diagnostic procedures generally uncover diseases only after clinical symptoms show, resulting in delayed interventions. In contrast, AI-enabled solutions, through integration with biosensors and Internet of Things (IoT) devices, facilitate continuous monitoring and early recognition of small physiological anomalies. Machine learning (ML) and deep learning (DL) algorithms can find non-linear connections within multidimensional datasets, aiding in the early diagnosis of cardiovascular problems, diabetes mellitus, sepsis, and neurodegenerative diseases by examining patterns in vital signs and behavioral data. Despite these gains, difficulties exist, including data heterogeneity, algorithmic bias, and limitations in training datasets, especially in marginalized populations. The interpretability of complicated AI models remains a major challenge, often limiting clinical acceptance. Additionally, legislative limits and concerns over data privacy provide impediments to wider implementation. Methodological shortcomings, such as the lack of defined data gathering techniques and insufficient longitudinal research, limit the generalizability of AI findings. Future directions should focus on federated learning, individualized predictive models, and the development of explainable AI frameworks. This paper critically explores present applications, technical limits, and future opportunities, emphasizing AI's promise to improve early disease diagnosis by monitoring homeostatic disruptions with precision and efficiency.

Keywords: Artificial intelligence, Homeostasis, Early disease detection, Machine learning, Predictive healthcare.

Received: 19-03-2025; **Accepted:** 23-04-2025; **Available Online**: 28-04-2025

1. Introduction

Homeostasis refers to the innate ability of biological systems to maintain a stable internal environment through the dynamic regulation of essential physiological variables such as temperature, pH, electrolyte balance, glucose content, and arterial pressure. This self-regulating mechanism is critical for ensuring cellular function, metabolic stability, and systemic resilience. The disruption of these closely controlled parameters, even if transitory or subclinical, may undermine physiological integrity and set the foundation for disease progression.[1]

1.1. Role of homeostatic imbalance in early disease onset

Persistent homeostatic imbalance often predates clinical diagnosis, serving as a forerunner to pathogenic signs. For example, chronic hyperglycemia is a hallmark of prediabetic conditions, and modest changes in heart rhythms may be indicative of arrhythmias or myocardial stress. These early disruptions, while often unnoticed by standard examination, possess crucial diagnostic importance. The potential to recognize such abnormalities at a fledgling stage is vital for enabling prompt therapeutic interventions and enhancing prognosis results.[2]

*Corresponding author: Sitaram Kale
Email: sitaramkale03@gmail.com

http://doi.org/10.18231/j.ijcap.2025.004

1.2. Limitations of conventional diagnostic approaches

Traditional diagnostic approaches rely largely on episodic measures, symptom-based assessment, and laboratory testing performed at distinct time points. Such techniques often fail to reflect the dynamic nature of physiological control and may ignore temporary but important aberrations. Additionally, the reliance on clinical interpretation creates uncertainty and delays, especially in asymptomatic or complex situations. These constraints underline the need for more continuous, tailored, and data-centric ways to measure and evaluate homeostatic changes.[3]

1.3. Emergence of artificial intelligence in homeostatic monitoring

Artificial Intelligence (AI), covering Machine Learning (ML), Deep Learning (DL), and data-driven inference models, has caused a paradigm shift in healthcare. Through real-time data integration from wearable biosensors, Internet of Things (IoT) devices, and electronic health records (EHRs), AI enables continuous surveillance of physiological measurements. By evaluating massive amounts of multidimensional data, AI systems can spot nonlinear trends and tiny perturbations suggestive of early-stage pathology. However, difficulties like as data heterogeneity, limited training datasets, algorithmic bias, and lack of model transparency persist. Addressing these concerns through federated learning frameworks, explainable AI models, and ethical data governance will be important for clinical translation.



Figure 1: AI-integrated pipeline for homeostatic disruption detection and early diagnosis[6]

This paper intends to critically analyze the role of AI in detecting homeostatic disruptions for early disease diagnosis, assessing present technologies, highlighting existing methodological shortcomings, and defining future paths for precision healthcare innovation. **Figure 1** illustrates the end-to-end AI-enabled workflow for continuous homeostatic monitoring and early disease diagnosis. Data acquired from biosensors and digital health systems are preprocessed and analyzed using AI algorithms to discover early physiological abnormalities. These disturbances are connected with disease risk profiles to provide actionable insights through a Clinical Decision Support System (CDSS), promoting early intervention and preventative therapy.[4,5]

2. Understanding Homeostasis and Its Disruption

Homeostasis is sustained through the exact regulation of various interdependent physiological factors, which collectively ensure the stability of the internal environment. Disruptions in these parameters, even within marginal limits, often signify the early initiation of disease processes. Among the most significant factors are body temperature, blood glucose levels, blood pressure, hydrogen ion concentration (pH), and electrolyte composition. Each parameter is carefully regulated by complicated feedback systems including neurological, endocrine, and cellular pathways.[1]

2.1. Key homeostatic parameters

2.1.1. Body temperature regulation and thermoregulatory instability

Body temperature is a fundamental sign of systemic balance, maintained through thermoregulatory systems including the hypothalamus, vasomotor activity, and metabolic heat production. Even slight differences may signal the presence of infections, inflammatory conditions, or metabolic abnormalities. Traditional monitoring procedures, however, are episodic and may overlook brief febrile increases. AI-enabled thermal pattern recognition, linked with real-time data from wearable sensors, presents a promising path for early anomaly detection, while it is currently restricted by sensor calibration concerns and the absence of longitudinal normative datasets.[7]

2.1.2. Glycemic homeostasis and early dysregulation of blood glucose levels

Blood glucose regulation is mediated by insulin-glucagon dynamics and is crucial to metabolic balance. Chronic increases, sometimes undiagnosed in prediabetic phases, are precursors to type 2 diabetes mellitus. Continuous glucose monitoring technologies, when paired with AI models, can identify abnormal glycemic variations, boosting predictive accuracy. Yet, data diversity among populations, food trends, and sensor discrepancies offer substantial training and generalization issues for these algorithms.[8]

2.1.3. Blood pressure variability and cardiovascular risk prediction

Blood pressure is another crucial metric, representing cardiovascular and renal function. Fluctuations, particularly in diurnal patterns, are substantially linked with early hypertension states and cardiovascular risk. AI-based models, trained on time-series data from ambulatory monitors, can detect minor anomalies suggestive of autonomic imbalance. However, the lack of defined input formats and uneven patient compliance restrict the robustness of such forecasts in clinical contexts.[9]

2.1.4. Acid-base balance and ph fluctuations in systemic disease

The management of pH, particularly within restricted physiological limits, is critical for enzyme activity and cellular function. Even small acid-base imbalances might suggest systemic sickness such as sepsis, renal failure, or breathing impairment. AI algorithms capable of analyzing arterial blood gas patterns can enable early diagnosis, but their efficiency is impeded by the infrequency of sampling and unpredictability in lab test procedures.[10]

2.1.5 Electrolyte homeostasis and ai-supported early detection of imbalances

Electrolyte balance—governed by renal, endocrine, and cellular transport mechanisms—is critical for neuromuscular function, hydration, and metabolic processes. Disruptions, such as hyperkalemia or hyponatremia, may present insidiously but may swiftly escalate to catastrophic states. AI models incorporating serum electrolyte trends with other homeostatic measures have proven potential in anticipating acute decompensation, particularly in critical care conditions. Nevertheless, data sparsity, inter-laboratory heterogeneity, and missing contextual information continue to restrict predictive reliability.[11]

2.2. Disease onset and homeostatic imbalance

2.2.1. Early indicators of chronic diseases

Chronic and acute diseases often originate from subtle, prolonged abnormalities in homeostasis. While typically asymptomatic, these early disturbances can predict future health problems. For example, persistent rises in fasting glucose may signal insulin resistance, a precursor to type 2 diabetes, while abnormalities in circadian rhythm, blood pressure, or heart rate variability may indicate a risk for cardiovascular, renal, or neurological issues. These early signs often go undetected by standard diagnostic techniques that rely on episodic testing and fail to account for dynamic physiological fluctuations.[12,13]

2.2.2. Necessity of continuous monitoring for predictive diagnostics

Continuous monitoring of physiological parameters offers a transformative method for predictive diagnostics by recording dynamic trends and early deviations before symptom manifestation. Unlike typical point-in-time examinations, real-time data collecting enables the discovery of slow pathological alterations, allowing for prompt interventions. This strategy is particularly crucial for illnesses with slow and progressive pathogenesis, because early treatment involvement can drastically modify disease trajectory. However, continuous monitoring at scale generates huge, complicated datasets that are impracticable for manual interpretation, necessitating the development of automated systems capable of contextual and temporal pattern recognition.[14]

2.2.3. Limitations of manual detection and traditional approaches

Manual identification of homeostatic imbalance is constrained by human perceptual limits, cognitive bias, and the complexity of multivariate data interpretation. Traditional models fail to capture nonlinear connections and temporal interactions among physiological systems. The absence of universally accepted diagnostic baselines—due to interindividual variability, lifestyle, and environmental factors—complicates early disease diagnosis. These issues underscore the need for intelligent, adaptable systems to analyze personalized health trajectories dynamically.[15]

2.2.4. Future directions and the role of artificial intelligence

Artificial Intelligence (AI), notably through Machine Learning (ML) and Deep Learning (DL) techniques, holds tremendous promise for real-time, data-driven homeostatic surveillance. AI systems are well-suited to assess high-volume, high-velocity data streams generated from biosensors, wearable devices, and electronic health records. Nevertheless, existing implementations are impeded by various constraints, including limited access to diverse, high-resolution longitudinal datasets, lack of defined data gathering techniques, and poor model interpretability. Ensuring equitable and effective implementation of AI in clinical contexts will need coordinated efforts in data governance, algorithmic openness, and interdisciplinary collaboration. Emphasis must be placed on developing explainable AI models that can enhance healthcare decision-making while preserving patient confidence and data privacy.[16]

3. AI Technologies for Homeostatic Monitoring

The integration of Artificial Intelligence (AI) technology into physiological monitoring systems has altered the landscape of preventive healthcare by providing continuous assessment of homeostatic stability. These technologies are capable of evaluating massive and complicated datasets collected from wearable devices, clinical records, and sensor-enabled surroundings to detect early disruptions in internal homeostasis. By analyzing small changes in biological signals, AI allows predictive diagnosis and rapid clinical intervention.

Table 1: Applications of AI in monitoring homeostatic disruption for early disease detection[18]

Physiological System	Homeostatic Parameter Monitored	Potential Disease Detected	AI Methodology Applied	Key Advantages
Cardiovascular	Heart rate variability, blood pressure	Arrhythmia, Hypertension, Heart failure	Supervised ML, DL (e.g., CNN, RNN)	Early prediction of cardiovascular events, risk stratification
Metabolic	Glucose levels, insulin sensitivity	Diabetes Mellitus Type I & II	Time-series ML models, Reinforcement Learning	Continuous glucose monitoring, personalized insulin dosing
Respiratory	Oxygen saturation, respiration rate	Chronic Obstructive Pulmonary Disease (COPD), Sleep apnea	Decision Trees, Support Vector Machines (SVM)	Non-invasive, real-time alerts for hypoxia or apnea
Neurological	Electroencephalogram (EEG) signals, cognitive metrics	Epilepsy, Alzheimer's Disease, Stroke	DL (CNN, LSTM), Unsupervised learning	Predictive seizure detection, early cognitive decline analysis
Immune/Inflam matory	Cytokine levels, body temperature, white cell count	Sepsis, Autoimmune disorders	Logistic Regression, Ensemble Learning	Early sepsis detection, automated infection monitoring
Renal	Electrolyte balance, creatinine, urea	Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD)	Classification models, DL regression	Early intervention before critical renal decline

This section discusses the key AI methodologies—beginning with Machine Learning (ML)—that are crucial in obtaining actionable insights from multidimensional physiological data streams for homeostatic monitoring and early illness identification. The **Table 1** Gives in briefly information about Applications of AI in Monitoring Homeostatic Disruption for Early Disease Detection.[17]

3.1. Machine learning (ML)

Machine Learning (ML), a basic component of AI, has proved important in evaluating complicated physiological information to discover early violations in homeostatic balance. By leveraging both supervised and unsupervised learning techniques, ML models are capable of extracting meaningful patterns from high-dimensional data streams acquired by wearable biosensors and clinical monitoring systems. These data sources provide continuous, real-time measurements of important factors such as heart rate, blood glucose levels, respiration rate, and core body temperature, which are essential indications of systemic homeostasis. One of the most impactful applications of ML in this context is its capacity to develop predictive models that forecast abnormal physiological trends before they reach pathological thresholds. For instance, temporal modeling employing decision trees, support vector machines, and ensemble approaches like random forests might forecast the commencement of cardiovascular or metabolic events by recognizing subtle, nonlinear connections within longitudinal health data. These models boost the sensitivity of early detection systems, enabling doctors to undertake preemptive therapies well before conventional diagnostic signs become apparent.[18]

The implementation of ML in homeostatic monitoring is not without its limits. The success of these models is largely dependent on the quality, volume, and representativeness of the training datasets. Data heterogeneity—arising from varied sensor types, ambient conditions, and individual variability—can limit model accuracy and generalizability. Moreover, the lack of uniform data labeling and the inclusion of noise or missing values provide considerable methodological hurdles. Another major challenge is the interpretability of ML results. While some algorithms offer openness in decision-making, more complicated models may act as "black boxes," limiting clinical trust and adoption. This issue underlines the need of establishing explainable ML frameworks that not only give excellent performance but also provide doctors with intelligible reasoning behind predictions. Additionally, ethical problems regarding data privacy, especially in the use of continuous personal health monitoring systems, must be addressed by effective encryption, decentralized data processing, and regulatory oversight.[19]

Future developments in this domain will likely require the incorporation of federated learning approaches, which allow collaborative model training across remote datasets without direct data exchange. This technique ensures patient anonymity while boosting model robustness across various populations. Moreover, merging ML with domain-specific expertise, such as physiological modeling or systems biology, may further boost the accuracy and contextual relevance of prediction systems. ML offers significant capabilities for real-time homeostatic disruption monitoring, enabling proactive healthcare through data-driven insights. Despite existing limitations in data quality, interpretability, and generalizability, continuing research and interdisciplinary collaboration are likely to develop these technologies, opening the door for more tailored and preventive diagnostic solutions.[20]

3.2. Deep learning (DL)

Deep Learning (DL), a subfield of Artificial Intelligence (AI), has substantially expanded the field of physiological monitoring by delivering sophisticated tools capable of learning hierarchical representations from high-dimensional data. Among DL designs, Convolutional Neural Networks (CNNs) have proven great success in interpreting complex biomedical imaging data. By leveraging spatial hierarchies and local receptive fields, CNNs can extract clinically relevant features from modalities such as magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound, enabling the early detection of anatomical or functional changes associated with homeostatic disruption. For instance, minor fluctuations in tissue perfusion, indicative of early cardiovascular anomalies or inflammatory processes, can be discovered by CNN-based image classification and segmentation pipelines with higher sensitivity than standard radiological examinations.[21]

Beyond static imaging, DL also plays a vital role in the temporal modeling of physiological data through time-series analysis. Recurrent Neural Networks (RNNs), and more recently, Long Short-Term Memory (LSTM) and Transformer-based architectures, have been applied to forecast swings in vital indicators such as heart rate variability, oxygen saturation, and blood glucose levels. These models excel in capturing long-range dependencies and nonlinear dynamics inherent in biological rhythms, therefore supporting predictive analytics in circumstances like arrhythmias, hypoglycemia, or sepsis development. By continually learning from longitudinal patient data, DL frameworks can produce early warning systems and adaptive monitoring tactics adapted to individual physiological baselines.[22]

The application of DL in clinical homeostasis monitoring is accompanied by considerable obstacles. A fundamental restriction resides in the demand for vast labeled datasets to ensure successful model generalization across varied populations. Many extant datasets are biased toward specific demographics or controlled clinical situations, limiting the external validity of DL models when applied in real-world, ambulatory settings. Furthermore, the "black-box" nature of DL algorithms often impedes interpretability, causing issues among doctors regarding trust, accountability, and regulatory compliance. Although approaches in explainable AI, such as saliency mapping and attention visualization, are being integrated to promote transparency, their use in physiological monitoring remains in its infancy. Future initiatives should highlight the integration of multimodal data sources—combining imaging, wearable sensor outputs, and electronic health records (EHRs)—to generate full patient profiles that reflect both structural and functional elements of homeostasis. Additionally, the deployment of federated learning architectures may alleviate data privacy problems while improving model robustness across institutions. As DL continues to evolve, its potential to change the early identification of disease through sensitive and dynamic surveillance of homeostatic parameters remains great, provided its limitations are systematically addressed through interdisciplinary collaboration and rigorous validation.[23]

3.3. Natural language processing (NLP)

Natural Language Processing (NLP), a branch of Artificial Intelligence (AI), plays a crucial role in extracting insights from unstructured text in Electronic Health Records (EHRs). Unlike structured data, EHRs contain narrative content—physician notes, symptom descriptions, and patient history—that is often underutilized in traditional analysis. NLP enables automated detection of early signs of homeostatic disruption that may not appear in measurable physiological data.[24] Advanced NLP algorithms, combining rule-based and machine learning approaches, identify semantic patterns and temporal relationships suggestive of emerging disorders. Clues like fluctuating blood pressure, dizziness, or sleep disturbances can indicate underlying instability. NLP also supports time-series analysis of symptom progression, and when integrated with AI tools like predictive modeling, enhances clinical decision support.[25]

Despite its potential, NLP faces challenges such as inconsistent documentation, domain-specific language, and lack of standardized terminologies. Issues in contextual disambiguation, cross-lingual processing, and model interpretability, particularly in critical care, remain significant. Data privacy and ethical concerns also complicate large-scale implementation.[26] Future efforts should focus on explainable NLP models to boost clinician trust and integration into workflows. Fine-tuning large pre-trained models on medical texts and combining NLP with structured data and biosensors could create a robust framework for early disease detection. NLP's continued advancement will be central to next-generation intelligent health monitoring systems.[27]

3.4. Internet of things (IoT) integration

The convergence of the Internet of Things (IoT) and Artificial Intelligence (AI) has revolutionized homeostatic monitoring by enabling continuous, real-time analysis of physiological data. Wearable and implantable biosensors—featuring miniaturized electronics, wireless connectivity, and biocompatible materials—monitor vital signs such as heart rate, oxygen saturation, glucose levels, and core temperature. These data streams are transmitted to cloud or edge-computing platforms, where AI algorithms perform dynamic trend analysis, detect anomalies, and generate predictive alerts to identify subclinical homeostatic disruptions.[28] A key advantage of this integration is remote monitoring, especially for individuals with chronic conditions, the elderly, or post-acute care patients. AI-driven alerts based on deviations from baseline can prompt early interventions or automated therapeutic responses, potentially preventing deterioration. However, several challenges hinder widespread adoption. Data quality can be compromised by noise, motion artifacts, or calibration errors. Additionally, issues with device interoperability, battery limitations, and network latency can affect data transmission and processing. Standardizing data collection and validating AI models across diverse populations remain critical hurdles.[29]

Ethical and regulatory challenges also persist, including concerns around data privacy, informed consent, and cybersecurity. The development of explainable AI is essential for gaining clinical trust and ensuring transparent, responsible decision-making. Future directions should prioritize adaptive learning systems, decentralized analytics through edge computing, and energy-efficient wearable technologies to enhance scalability and sustainability. As these innovations evolve, they promise to shift healthcare from reactive to proactive, enabling early detection of disease pathways before clinical manifestation.[30,31]

4. Applications in Early Disease Detection

The integration of Artificial Intelligence (AI) into clinical frameworks has considerably boosted the early identification and prediction modeling of numerous diseases by enabling real-time interpretation of small physiological aberrations that suggest homeostatic instability. AI-driven diagnostic tools leverage large-scale data analytics, including pattern recognition and temporal modeling, to detect early biomarkers and functional abnormalities across a broad range of disorders. The following subsections address how AI has been applied to distinct domains of disease detection, with emphasis on methodological improvements, clinical significance, and existing obstacles.[32]

4.1. Cardiovascular diseases

In cardiovascular medicine, AI has showed extraordinary capability in the early diagnosis of arrhythmogenic disorders and heart failure through the analysis of electrocardiogram (ECG) data, heart rate variability (HRV), and blood pressure dynamics. By applying deep learning (DL) architectures, particularly convolutional neural networks (CNNs) and recurrent neural networks (RNNs), AI systems can detect subtle waveform anomalies and nonlinear fluctuations predictive of atrial fibrillation and ventricular dysfunction before clinical symptoms manifest. Additionally, continuous monitoring of HRV and systolic-diastolic rhythms via wearable sensors has enabled for dynamic risk assessment. However, the translation of these models into routine care is restricted by inter-individual variability, dataset imbalances, and poor explainability, necessitating the creation of more interpretable frameworks and multi-center validation studies.[33,34]

4.2. Diabetes mellitus

AI has considerably enhanced the management of diabetes mellitus by enabling continuous glucose monitoring (CGM) and real-time predictive modeling of diabetic excursions. Algorithms trained on CGM datasets, in conjunction with behavioral and nutritional input, have been applied to foresee hypoglycemia and hyperglycemic events with great sensitivity, thereby helping proactive therapeutic decision-making. Reinforcement learning models and long short-term memory (LSTM) networks have also been employed to optimize insulin administration in closed-loop systems. Despite these gains, algorithmic generalizability across varied groups remains limited due to variability in insulin sensitivity, comorbidities, and lifestyle factors. Future developments should focus adaptive learning methods and federated data frameworks to promote personalization while respecting data privacy.[35]

4.3. Sepsis and infections

The early diagnosis of sepsis, a syndrome characterized by systemic inflammatory response and multi-organ failure, is crucial for improving patient outcomes in intensive care units (ICUs). AI models have been implemented to assess real-time vital sign fluctuations—including respiration rate, body temperature, blood pressure, and white blood cell count—to identify prodromal patterns indicative of sepsis development. These models, frequently based on gradient boosting and ensemble learning approaches, can trigger automatic alarms for therapeutic intervention prior to the beginning of overt organ failure. Although these tools have proven potential in retrospective validation, prospective integration into ICU operations is hindered by uneven data quality, sensor artifacts, and clinical inertia. Continued development of context-aware algorithms and thorough validation across various ICU situations will be important for scalable application.[36]

4.4. Neurodegenerative disorders

In the setting of neurodegenerative disorders such as Parkinson's and Alzheimer's, AI has aided the identification of preclinical biomarkers through multimodal analysis of speech, motor function, and cognitive decline. AI-enabled speech analysis detects microvariations in pitch, rhythm, and articulation, whereas gait analysis systems examine kinematic data to recognize early motor damage. Support vector machines (SVMs), DL models, and ensemble classifiers have been applied to discern between normal aging and pathological decline with increasing accuracy. However, the absence of rigorous diagnostic norms and the subjective nature of symptom annotation impede model reliability. Future research must overcome these gaps by integrating neuroimaging, genetic, and behavioral data into unified predictive platforms.[37,38]

4.5. Oncology

AI has considerably increased early cancer detection by boosting the resolution and interpretability of medical imaging and biomarker analysis. Radiomics-based AI algorithms extract high-dimensional information from imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET), enabling the diagnosis of cancers at an incipient stage. Furthermore, supervised learning techniques have been applied to genomic and proteomic data to discover oncogenic signals indicative of early cancer. While these technologies offer great diagnostic precision, their clinical application is restricted by diversity in imaging methods, lack of data harmonization, and the need for large annotated datasets. Interdisciplinary collaboration and longitudinal research are crucial to enhance these tools for early intervention and individualized oncologic therapy.[39,40]

5. Challenges and Limitations

The integration of Artificial Intelligence (AI) into healthcare systems for monitoring homeostatic disturbance and promoting early disease identification involves a plethora of issues that include data integrity, technical feasibility, regulatory compliance, and ethical accountability. While AI has significant diagnostic accuracy and predictive potential, its widespread clinical application is impeded by many important limitations that must be solved to enable safe, effective, and equitable deployment.[41]

5.1. Data issues

The development and validation of AI models in healthcare depend on access to large, diverse, and high-quality datasets. However, many existing datasets are limited, often derived from homogenous populations or single institutions, reducing generalizability. Lack of demographic and clinical variability can lead to biased predictions and poor real-world performance. Additionally, inconsistencies in data collection, missing values, and inadequate annotations introduce noise, undermining model reliability.[42] Privacy and security concerns further restrict data access. Compliance with regulations like HIPAA and GDPR is essential but can hinder data sharing and cross-institution collaboration. Emerging solutions such as federated learning and privacy-preserving computation allow decentralized model training without direct data exchange but remain complex and resource-intensive to implement.[43]

5.2. Technical and ethical challenges

Technical issues, including algorithmic bias and limited interpretability, challenge the clinical utility of AI. Biased datasets can perpetuate health disparities, and the opaque nature of deep learning models hinders clinician trust by obscuring decision-making processes. This lack of transparency complicates integration into clinical workflows where explainability is critical.[44] Regulatory frameworks also lag behind the needs of evolving AI systems, particularly those capable of post-deployment learning. New evaluation protocols are needed to balance safety, efficacy, and innovation. Ethically, delegating decisions to AI raises concerns about liability, informed consent, and the erosion of the clinician-patient relationship. AI must enhance—not replace—clinical judgment, maintaining human oversight in care decisions.[45] While AI holds great promise for early disease detection and homeostatic monitoring, its clinical adoption requires stringent focus on data quality, model transparency, regulatory adaptation, and ethical integrity. Addressing these challenges through interdisciplinary collaboration and adaptive policy will be key to unlocking AI's full potential in precision medicine.[46]

6. Future Perspectives

The advancement of Artificial Intelligence (AI) in healthcare calls for a forward-thinking approach emphasizing precision, scalability, and clinical relevance. A key development is the creation of personalized AI models that consider individual variability in physiological baselines, genetic traits, lifestyle, and environmental factors. Unlike population-level algorithms, personalized models can adapt to a person's unique profile, enhancing sensitivity and specificity in detecting early homeostatic changes. These models utilize longitudinal data to establish adaptive thresholds for abnormalities, moving beyond static clinical cut-offs. Another pivotal frontier is the integration of AI with wearable closed-loop devices, combining real-time biosensing, automated feedback, and AI-driven decision-making. These systems allow for early detection of physiological disruptions and immediate interventions—such as medication adjustments or behavioral prompts—without manual input. This is especially useful for chronic conditions like diabetes and hypertension, where tight physiological control is critical. Challenges remain, including sensor reliability, energy efficiency, and data synchronization for sustained use.[47,48,49,50]

Despite the promise, methodological and practical challenges persist. Data heterogeneity, limited access to high-quality annotated datasets, and poor integration with clinical workflows hinder progress. Ensuring model interpretability, minimizing bias, and implementing rigorous validation are essential for clinician trust and regulatory approval. Future research must prioritize interdisciplinary collaboration to create AI solutions that are technically robust, ethically sound, and clinically actionable.[51] The future of AI in homeostatic monitoring and early disease detection lies in transitioning from static, retrospective analysis to dynamic, patient-centered systems. By leveraging personalized models, closed-loop technologies, and privacy-preserving frameworks like federated learning, AI can redefine preventative medicine and usher in a more anticipatory, individualized healthcare paradigm.[52]

7. Conclusion

Artificial Intelligence (AI), comprising technologies such as Machine Learning (ML), Deep Learning (DL), and Natural Language Processing (NLP), has emerged as a disruptive force in predictive healthcare. By enabling continuous, real-time analysis of complicated physiological data streams, AI presents a great opportunity to discover early departures in homeostasis—subtle disturbances that often precede the emergence of overt pathology. This capability allows healthcare to develop from a typically reactive model, focused on treating diseases post-symptomatically, toward a preventive and proactive paradigm that prioritizes early intervention and risk avoidance. The integration of AI into homeostatic monitoring systems has proven tremendous potential across multiple therapeutic domains, including cardiovascular illness, metabolic diseases, sepsis, and neurodegeneration. These applications exploit AI's ability to find latent patterns in high-dimensional datasets gathered from biosensors, electronic health records (EHRs), and Internet of Things (IoT) devices. However, despite these gains, numerous fundamental constraints remain. Data heterogeneity, limited longitudinal datasets, and underrepresentation of varied patient populations hamper the generalizability and robustness of AI models. Additionally, algorithmic opacity and the lack of explainability continue to limit clinical uptake and regulatory approval, creating valid concerns about safety, accountability, and ethical deployment. Addressing these methodological gaps would need not only advancements in computational science but also robust multidisciplinary collaboration among physicians, data scientists, engineers, ethicists, and policy-makers. The creation of transparent, interpretable, and egalitarian AI systems must be led by clinical relevance and user-centric design principles. Furthermore, future research should focus on federated learning architectures, privacy-preserving data sharing, and context-aware modeling to support safe, scalable, and customized diagnoses. Ultimately, AI has the ability to alter healthcare delivery by transforming homeostatic monitoring into a cornerstone of precision medicine, greatly increasing early disease diagnosis, clinical decision-making, and long-term patient outcomes.

8. Source of Funding

None.

9. Conflict of Interest

None.

References

1. Billman GE. Homeostasis: The Underappreciated and Far Too Often Ignored Central Organizing Principle of Physiology. *Front Physiol*. 2020;11:200.
2. Alvarez S, Coffey R, Mathias PM, et al. Prediabetes. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459332/
3. Orndorff-Plunkett F, Singh F, Aragón OR, Pineda JA. Assessing the Effectiveness of Neurofeedback Training in the Context of Clinical and Social Neuroscience. *Brain Sci*. 2017;7(8):95. doi:10.3390/brainsci7080095
4. Chakraborty C, Bhattacharya M, Pal S, Lee SS. From machine learning to deep learning: Advances of the recent data-driven paradigm shift in medicine and healthcare. *Curr Res Biotechnol*. 2023;7:100164. https://doi.org/10.1016/j.crbiot.2023.100164.
5. Rahman A, Debnath T, Kundu D, Khan MSI, Aishi AA, Sazzad S et al. Machine learning and deep learning-based approach in smart healthcare: Recent advances, applications, challenges and opportunities. *AIMS Public Health*. 2024;11(1):58-109. doi:10.3934/publichealth.2024004
6. Yang S, Kar S. Application of artificial intelligence and machine learning in early detection of adverse drug reactions (ADRs) and drug-induced toxicity. *Artif Intell Chem*. 2023;1(2):100011. https://doi.org/10.1016/j.aichem.2023.100011.
7. Tan CL, Knight ZA. Regulation of Body Temperature by the Nervous System. *Neuron*. 2018;98(1):31-48. doi:10.1016/j.neuron.2018.02.022
8. Crecil Dias C, Kamath S, Vidyasagar S. Blood glucose regulation and control of insulin and glucagon infusion using single model predictive control for type 1 diabetes mellitus. *IET Syst Biol*. 2020;14(3):133-46. doi:10.1049/iet-syb.2019.0101
9. Al-Alusi MA, Friedman SF, Kany S, Rämö JT, Pipilas D, Singh P et al. A deep learning digital biomarker to detect hypertension and stratify cardiovascular risk from the electrocardiogram. *NPJ Digit Med*. 2025;8(1):120. doi:10.1038/s41746-025-01491-8
10. Anwar S, Alrumaihi F, Sarwar T, Babiker AY, Khan AA, Prabhu SV, et al. Exploring Therapeutic Potential of Catalase: Strategies in Disease Prevention and Management. *Biomolecules*. 2024;14(6):697. https://doi.org/10.3390/biom14060697
11. Ernstmeyer K, Christman E, editors. Nursing fundamentals [Internet]. Eau Claire (WI): Chippewa Valley Technical College; 2021. Chapter 15, Fluids and electrolytes. Available from: https://www.ncbi.nlm.nih.gov/books/NBK591820/
12. Drüeke TB. Hyperparathyroidism in Chronic Kidney Disease. [Updated 2025 Feb 14]. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK278975/
13. Wang S, Qin L. Homeostatic medicine: a strategy for exploring health and disease. *Curr Med (Cham)*. 2022;1(1):16. doi:10.1007/s44194-022-00016-9
14. Shusharina N, Yukhnenko D, Botman S, Sapunov V, Savinov V, Kamyshov G et al. Modern Methods of Diagnostics and Treatment of Neurodegenerative Diseases and Depression. *Diagnostics (Basel)*. 2023;13(3):573. doi:10.3390/diagnostics13030573
15. Vergallito A, Feroldi S, Pisoni A, Romero Lauro LJ. Inter-Individual Variability in tDCS Effects: A Narrative Review on the Contribution of Stable, Variable, and Contextual Factors. *Brain Sci*. 2022;12(5):522. doi:10.3390/brainsci12050522
16. Pettit RW, Fullem R, Cheng C, Amos CI. Artificial intelligence, machine learning, and deep learning for clinical outcome prediction. Emerg Top Life Sci. *Emerg Top Life Sci*. 2021;5(6):729-45. doi:10.1042/ETLS20210246
17. Bajwa J, Munir U, Nori A, Williams B. Artificial intelligence in healthcare: transforming the practice of medicine. *Future Healthc J*. 2021;8(2):e188-94. doi:10.7861/fhj.2021-0095
18. Woodman RJ, Mangoni AA. A comprehensive review of machine learning algorithms and their application in geriatric medicine: present and future. *Aging Clin Exp Res*. 2023;35(11):2363-97.
19. Amiri Z, Heidari A, Darbandi M, Yazdani Y, Navimipour NN, Esmaeilpour M et al. The Personal Health Applications of Machine Learning Techniques in the Internet of Behaviors. *Sustainability*. 2023;15:12406.
20. Papadopoulos C, Kollias KF, Fragulis GF. Recent Advancements in Federated Learning: State of the Art, Fundamentals, Principles,

IoT Applications and Future Trends. *Future Internet* 2024;16(11):415.
21. Yang S, Kar S. Application of artificial intelligence and machine learning in early detection of adverse drug reactions (ADRs) and drug-induced toxicity. *Artif Intelligence Chem*. 2023;1(2):100011.
22. Waqas M, Humphries UW. A critical review of RNN and LSTM variants in hydrological time series predictions. *MethodsX*. 2024;13:102946.
23. Li M, Jiang Y, Zhang Y, Zhu H. Medical image analysis using deep learning algorithms. *Front Public Health*. 2023;11:1273253.
24. Hossain E, Rana R, Higgins N, Soar J, Barua PD, Pisani AR, et al. Natural Language Processing in Electronic Health Records in relation to healthcare decision-making: A systematic review. *Comput Biol Med*. 2023;155:106649.
25. Al-Garadi MA, Yang YC, Sarker A. The Role of Natural Language Processing during the COVID-19 Pandemic: Health Applications, Opportunities, and Challenges. *Healthcare* 2022;10(11):2270.
26. Alzubaidi L, Bai J, Al-Sabaawi A, Santamaría J, Albahri AS, Al-dabbagh BSN, et. al. A survey on deep learning tools dealing with data scarcity: definitions, challenges, solutions, tips, and applications. *J Big Data*. 2023;10:46.
27. Nassiri K, Akhloufi MA. Recent Advances in Large Language Models for Healthcare. *Bio Med Informatics*. 2024;4(2):1097-143.
28. Wang WH, Hsu WS. Integrating Artificial Intelligence and Wearable IoT System in Long-Term Care Environments. *Sensors*. 2023;23(13)5913.
29. Borna S, Maniaci MJ, Haider CR, Gomez-Cabello CA, Pressman SM, Haider SA et al. Artificial Intelligence Support for Informal Patient Caregivers: A Systematic Review. *Bioengineering (Basel)*. 2024;11(5):483.
30. Goktas P, Grzybowski A. Shaping the Future of Healthcare: Ethical Clinical Challenges and Pathways to Trustworthy AI. *J Clin Med*. 2025;14(5):1605.
31. Mennella C, Maniscalco U, De Pietro G, Esposito M. Ethical and regulatory challenges of AI technologies in healthcare: A narrative review. *Heliyon*. 2024;10(4):e26297.
32. Aravazhi PS, Gunasekaran P, Benjamin NZY, Thai A, Chandrasekar KK, Kolanu ND, et al. The integration of artificial intelligence into clinical medicine: Trends, challenges, and future directions. *Dis Mon*. 2025:101882.
33. Martínez-Sellés M, Marina-Breysse M. Current and Future Use of Artificial Intelligence in Electrocardiography. *J Cardiovasc Dev Dis*. 2023;10(4):175.
34. Khan Mamun MMR, Elfouly T. AI-Enabled Electrocardiogram Analysis for Disease Diagnosis. *Appl Syst Innov*. 2023;6(5):95.
35. Guan Z, Li H, Liu R, Cai C, Liu Y, Li, J, et al. Artificial intelligence in diabetes management: Advancements, opportunities, and challenges. *Cell Rep Med*. 2023;4(10):101213.
36. Yang J, Hao S, Huang J, Chen T, Liu R, Zhang P et al. The application of artificial intelligence in the management of sepsis. Med Rev (2021). 2023;3(5):369-80
37. Chudzik A, Śledzianowski A, Przybyszewski AW. Machine Learning and Digital Biomarkers Can Detect Early Stages of Neurodegenerative Diseases. *Sensors (Basel*). 2024;24(5):1572.
38. Qadri YA, Ahmad K, Kim SW. Artificial General Intelligence for the Detection of Neurodegenerative Disorders. *Sensors (Basel)*. 2024;24(20):6658.
39. Bi WL, Hosny A, Schabath MB, et al. Artificial intelligence in cancer imaging: Clinical challenges and applications. *CA Cancer J Clin*. 2019;69(2):127-57.
40. Pinto-Coelho L. How Artificial Intelligence Is Shaping Medical Imaging Technology: A Survey of Innovations and Applications. *Bioengineering (Basel)*. 2023;10(12):1435.
41. Alowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. *BMC Med Educ*. 2023;23:689.
42. Arora A, Alderman JE, Palmer J, Ganapathi S, Laws E, McCradden MD, et al. The value of standards for health datasets in artificial intelligence-based applications. *Nat Med*. 2023;29(11):2929-38.
43. Edemekong PF, Annamaraju P, Afzal M, Haydel MJ. Health Insurance Portability and Accountability Act (HIPAA) Compliance. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK500019/
44. Chen P, Wu L, Wang L. AI Fairness in Data Management and Analytics: A Review on Challenges, Methodologies and Applications*. Appl Sci*. 2023;13(18):10258.
45. Ahmed MI, Spooner B, Isherwood J, Lane M, Orrock E, Dennison A. A Systematic Review of the Barriers to the Implementation of Artificial Intelligence in Healthcare. *Cureus*. 2023;15(10):e46454.
46. Bekbolatova M, Mayer J, Ong CW, Toma M. Transformative Potential of AI in Healthcare: Definitions, Applications, and Navigating the Ethical Landscape and Public Perspectives. *Healthcare (Basel)*. 2024;12(2):125.
47. Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, et al. Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. *Pharmaceutics*. 2024;16(3):332.
48. Shajari S, Kuruvinashetti K, Komeili A, Sundararaj U. The Emergence of AI-Based Wearable Sensors for Digital Health Technology: A Review. *Sensors (Basel)*. 2023;23(23):9498.
49. Vo DK, Trinh KTL. Advances in Wearable Biosensors for Healthcare: Current Trends, Applications, and Future Perspectives*. Biosensors* 2024;14(11):560.
50. Pati S, Kumar S, Varma A, Edwards B, Lu C, Qu L, et al. Privacy preservation for federated learning in health care. *Patterns*. 2024;5(7):100974.
51. Aldoseri A, Al-Khalifa KN, Hamouda AM. Re-Thinking Data Strategy and Integration for Artificial Intelligence: Concepts, Opportunities, and Challenges. Appl Sci. 2023;13(12):7082.
52. Gala D, Behl H, Shah M, Makaryus AN. The Role of Artificial Intelligence in Improving Patient Outcomes and Future of Healthcare Delivery in Cardiology: A Narrative Review of the Literature. Healthcare (Basel). 2024;12(4):481.

Cite this article Ramdas K P, Phade S, Mundphane A, Kale S, Mane D, Survase A. Role of artificial intelligence in homeostatic disruption monitoring & Early disease detection. *Indian J Clin Anat Physiol.* 2025;12(1):14-22.